LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 239.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,833 shares of the medical instruments supplier's stock after purchasing an additional 6,937 shares during the quarter. Arrowstreet Capital Limited Partnership's holdings in LeMaitre Vascular were worth $906,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in LMAT. Smartleaf Asset Management LLC grew its position in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC lifted its stake in LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares during the period. KBC Group NV grew its holdings in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares in the last quarter. Empowered Funds LLC purchased a new position in LeMaitre Vascular during the 4th quarter valued at about $150,000. Finally, SG Americas Securities LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter valued at about $158,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Remove Ads

LeMaitre Vascular Stock Up 1.0 %

Shares of LMAT traded up $0.85 during mid-day trading on Tuesday, hitting $84.63. 145,216 shares of the company traded hands, compared to its average volume of 159,288. The business has a 50 day moving average of $88.88 and a 200 day moving average of $93.68. The company has a market capitalization of $1.91 billion, a PE ratio of 46.25, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LMAT shares. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target for the company. Finally, Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of "Moderate Buy" and an average price target of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.